Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer

被引：3

作者：

Du, Zhenfang ^{[1
]}

Sun, Jinghan ^{[2
]}

Zhang, Yunkai ^{[3
]}

Hesilaiti, Nigaerayi ^{[1
]}

Xia, Qi ^{[1
]}

Cui, Heqing ^{[4
]}

Fan, Na ^{[5
]}

Xu, Xiaofang ^{[6
]}

机构：

[1] Southeast Univ, Sch Med, Dept Genet & Dev Biol, Nanjing 210003, Peoples R China

[2] Southeast Univ, Sch Life Sci & Technol, Nanjing 210018, Peoples R China

[3] BioSpatula LLC, Telford, PA 18969 USA

[4] Nanjing Med Univ, Nanjing Chest Hosp, Dept Radiotherapy, Affiliated Brain Hosp, Nanjing 210029, Peoples R China

[5] Xi An Jiao Tong Univ, Dept Resp Med & Crit Care Med, Affiliated Hosp 2, Xian 710004, Peoples R China

[6] Chinese Acad Sci, Zhejiang Canc Hosp, Inst Basic Med & Canc IBMC, Dept Thorac Surg,Canc Hosp Univ Chinese Acad Sci, Hangzhou 310022, Peoples R China

来源：

BIOMOLECULES | 2023年 / 13卷 / 02期

关键词：

non-small cell lung cancer; EGFR; structure; targeted therapy; FACTOR-RECEPTOR MUTATIONS; TYROSINE KINASE INHIBITORS; 20 INSERTION MUTATIONS; EXON; 18; MUTATIONS; CLINICOPATHOLOGICAL CHARACTERISTICS; DOMAIN DUPLICATION; CLINICAL ACTIVITY; 1ST-LINE TREATMENT; PRIMARY RESISTANCE; AFATINIB TREATMENT;

D O I：

10.3390/biom13020210

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Oncogenic mutations within the EGFR kinase domain are well-established driver mutations in non-small cell lung cancer (NSCLC). Small-molecule tyrosine kinase inhibitors (TKIs) specifically targeting these mutations have improved treatment outcomes for patients with this subtype of NSCLC. The selectivity of these targeted agents is based on the location of the mutations within the exons of the EGFR gene, and grouping mutations based on structural similarities has proved a useful tool for conceptualizing the heterogeneity of TKI response. Structure-based analysis of EGFR mutations has influenced TKI development, and improved structural understanding will inform continued therapeutic development and further improve patient outcomes. In this review, we summarize recent progress on targeted therapy strategies for patients with EGFR-mutant NSCLC based on structure and function analysis.

引用

页数：16

共 115 条

[71] Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial [J].

Rosell, Rafael ;

Carcereny, Enric ;

Gervais, Radj ;

Vergnenegre, Alain ;

Massuti, Bartomeu ;

Felip, Enriqueta ;

Palmero, Ramon ;

Garcia-Gomez, Ramon ;

Pallares, Cinta ;

Miguel Sanchez, Jose ;

Porta, Rut ;

Cobo, Manuel ;

Garrido, Pilar ;

Longo, Flavia ;

Moran, Teresa ;

Insa, Amelia ;

De Marinis, Filippo ;

Corre, Romain ;

Bover, Isabel ;

Illiano, Alfonso ;

Dansin, Eric ;

de Castro, Javier ;

Milella, Michele ;

Reguart, Noemi ;

Altavilla, Giuseppe ;

Jimenez, Ulpiano ;

Provencio, Mariano ;

Angel Moreno, Miguel ;

Terrasa, Josefa ;

Munoz-Langa, Jose ;

Valdivia, Javier ;

Isla, Dolores ;

Domine, Manuel ;

Molinier, Olivier ;

Mazieres, Julien ;

Baize, Nathalie ;

Garcia-Campelo, Rosario ;

Robinet, Gilles ;

Rodriguez-Abreu, Delvys ;

Lopez-Vivanco, Guillermo ;

Gebbia, Vittorio ;

Ferrera-Delgado, Lioba ;

Bombaron, Pierre ;

Bernabe, Reyes ;

Bearz, Alessandra ;

Artal, Angel ;

Cortesi, Enrico ;

Rolfo, Christian ;

Sanchez-Ronco, Maria ;

Drozdowskyj, Ana .

LANCET ONCOLOGY, 2012, 13 (03) :239-246

[72] Altered conformational landscape and dimerization dependency underpins the activation of EGFR by αC-β4 loop insertion mutations [J].

Ruan, Zheng ;

Kannan, Natarajan .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (35) :EB162-EB171

[73] Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial [J].

Schuler, M. ;

Yang, J. C. -H. ;

Park, K. ;

Kim, J. -H. ;

Bennouna, J. ;

Chen, Y. -M. ;

Chouaid, C. ;

De Marinis, F. ;

Feng, J. -F. ;

Grossi, F. ;

Kim, D. -W. ;

Liu, X. ;

Lu, S. ;

Strausz, J. ;

Vinnyk, Y. ;

Wiewrodt, R. ;

Zhou, C. ;

Wang, B. ;

Chand, V. K. ;

Planchard, D. .

ANNALS OF ONCOLOGY, 2016, 27 (03) :417-423

[74] Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer withEGFR-G719Aand Other UncommonEGFRMutations [J].

Sehgal, Kartik ;

Rangachari, Deepa ;

VanderLaan, Paul A. ;

Kobayashi, Susumu S. ;

Costa, Daniel B. .

ONCOLOGIST, 2021, 26 (04) :281-287

[75] Transitions to catalytically inactive conformations in EGFR kinase [J].

Shan, Yibing ;

Arkhipov, Anton ;

Kim, Eric T. ;

Pan, Albert C. ;

Shaw, David E. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (18) :7270-7275

[76] Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization [J].

Shan, Yibing ;

Eastwood, Michael P. ;

Zhang, Xuewu ;

Kim, Eric T. ;

Arkhipov, Anton ;

Dror, Ron O. ;

Jumper, John ;

Kuriyan, John ;

Shaw, David E. .

CELL, 2012, 149 (04) :860-870

[77] Epidermal growth factor receptor mutations in lung cancer [J].

Sharma, Sreenath V. ;

Bell, Daphne W. ;

Settleman, Jeffrey ;

Haber, Daniel A. .

NATURE REVIEWS CANCER, 2007, 7 (03) :169-181

[78] Clinicopathologic characteristics and prognostic impact of atypical EGFR mutations in completely resected lung adenocarcinoma [J].

She, Yunlang ;

Li, Shenghui ;

Deng, Jiajun ;

Ren, Yijiu ;

Zhao, Mengmeng ;

Zhong, Yifan ;

He, Yiming ;

Chen, Qiankun ;

Zhao, Deping ;

Zhu, Yuming ;

Hou, Likun ;

Wu, Chunyan ;

Xie, Dong ;

Chen, Chang .

EUROPEAN JOURNAL OF CANCER, 2022, 177 :53-62

[79] Real-world clinical treatment outcomes in Chinese non-small cell lung cancer with EGFR exon 20 insertion mutations [J].

Shi, Chao ;

Xing, Ruyue ;

Li, Mengmeng ;

Feng, Junnan ;

Sun, Rui ;

Wei, Bing ;

Guo, Yongjun ;

Ma, Jie ;

Wang, Huijuan .

FRONTIERS IN ONCOLOGY, 2022, 12

[80] Safety, Clinical Activity, and Pharmacokinetics of Al flutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation [J].

Shi, Yuankai ;

Zhang, Shucai ;

Hu, Xingsheng ;

Feng, Jifeng ;

Ma, Zhiyong ;

Zhou, Jianying ;

Yang, Nong ;

Wu, Lin ;

Liao, Wangjun ;

Zhong, Dafang ;

Han, Xiaohong ;

Wang, Ziping ;

Zhang, Xiaodong ;

Qin, Shukui ;

Ying, Kejing ;

Feng, Jian ;

Fang, Jian ;

Liu, Li ;

Jiang, Yong .

JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (06) :1015-1026

← 3 4 5 6 7 8 9 10 11 12 →